ESC 365 - Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal PRO

ESC Premium Access

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal PRO

Session: First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

Topic: Pharmacotherapy

Speaker: Doctor M. Packer (Dallas, US)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor Milton Packer

Baylor University Medical Center, Dallas (United States of America)

42 presentations

4 followers

7 more presentations in this session

Opening question.

Positioning of the topic - First-line therapies in heart failure with reduced ejection fraction (HFrEF)

Speaker: Professor G. Filippatos (Athens, GR)

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - PRO

Speaker: Doctor M. Packer (Dallas, US)

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - CON

Speaker: Professor A. Voors (Groningen, NL)

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal CON

Speaker: Professor A. Voors (Groningen, NL)

Access the full session

First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

Speakers: Doctor M. Packer, Professor G. Filippatos, Doctor M. Packer, Professor A. Voors, Professor A. Voors

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

Related content

Open Access

Evidence-based strategies to achieve low-risk status.

27 August 2021

ESC Premium Access

Approach to the patient with pulmonary hypertension: essential knowledge.

27 August 2021

Open Access

Your treatment approach in clinical practice.

27 August 2021

ESC 365 is supported by